PROM1 and cancer: The synergistic effect of an antisense sequence and an anticancer drug are likely to provide a good alternative treatment against CD133+ cancer since downregulation of the CD133 protein may result in chemosensitization of cancer cell lines, as observed in the B16F10 cell line used in this study.